Suwalska A, Rybakowski J
Kliniki Psychiatrii Dorosłych AM w Poznaniu.
Psychiatr Pol. 1996 Sep-Oct;30(5):713-29.
The authors review recent findings concerning biological mechanisms of drug-resistant depression. Treatment-resistant depression may result from the inability of antidepressants to normalize serotonergic transmission. Efficacy of therapeutic strategies enhancing serotonergic function such as potentiation of tricyclic antidepressants with lithium or fluoxetine as well as effectiveness of selective serotonin reuptake inhibitors in drug-resistant depression may support this hypothesis. Limbic-hypothalamic-pituitary-adrenal axis hyperactivity may be also an important factor of the persistence of depression, and so treatment with inhibitors of steroid biosynthesis may bring about readjustment of this axis and remission of depression in some cases of drug-resistant depression with hypercortisolemia. Another subtype of drug-resistant depression may be related to a dysfunction of hypothyroidism. Some evidence suggests also a relationship between drug resistance in depression and changes in the immune system. Research on biological mechanisms of drug-resistant depression may help clinicians to decide on the most appropriate treatment strategy in resistant depression as well as to shed light on the pathomechanism of depression.
作者回顾了有关耐药性抑郁症生物学机制的近期研究发现。难治性抑郁症可能是由于抗抑郁药无法使血清素能传递正常化所致。增强血清素能功能的治疗策略(如用锂或氟西汀增强三环类抗抑郁药的效果)以及选择性5-羟色胺再摄取抑制剂在耐药性抑郁症中的有效性可能支持这一假说。边缘系统-下丘脑-垂体-肾上腺轴功能亢进也可能是抑郁症持续存在的一个重要因素,因此,在某些伴有高皮质醇血症的耐药性抑郁症病例中,使用类固醇生物合成抑制剂进行治疗可能会使该轴重新调整并使抑郁症缓解。耐药性抑郁症的另一种亚型可能与甲状腺功能减退功能障碍有关。一些证据还表明抑郁症的耐药性与免疫系统变化之间存在关联。对耐药性抑郁症生物学机制的研究可能有助于临床医生确定耐药性抑郁症最合适的治疗策略,并阐明抑郁症的发病机制。